Personalization of Chemotherapy for Metastatic Pancreatic Cancer

Erlotinib is an approved drug for the treatment of advanced pancreatic cancer; however, its survival benefit is small and its cost is high, and the decision to use the drug may often be personalized according to the patient’s background. A 72-year-old Asian man in good general condition chose gemcit...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasahara, Yuriko (Ito), Narimatsu, Hiroto, Suzuki, Syuhei, Fukui, Tadahisa, Sato, Hideyuki, Shirahata, Nakao, Yoshioka, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4116360/
https://www.ncbi.nlm.nih.gov/pubmed/25093005
http://dx.doi.org/10.4137/CCRep.S14478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4116360/
https://www.ncbi.nlm.nih.gov/pubmed/25093005
http://dx.doi.org/10.4137/CCRep.S14478

Ejemplares similares